- Open Access
The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice
© San Román et al.; licensee BioMed Central Ltd. 2012
- Received: 7 February 2012
- Accepted: 29 March 2012
- Published: 19 April 2012
The Extradomain A from fibronectin (EDA) has an immunomodulatory role as fusion protein with viral and tumor antigens, but its effect when administered with bacteria has not been assessed. Here, we investigated the adjuvant effect of EDA in mice immunizations against Salmonella enterica subspecies enterica serovar Enteritidis (Salmonella Enteritidis). Since lipopolysaccharide (LPS) is a major virulence factor and the LPS O-polysaccharide (O-PS) is the immunodominant antigen in serological diagnostic tests, Salmonella mutants lacking O-PS (rough mutants) represent an interesting approach for developing new vaccines and diagnostic tests to differentiate infected and vaccinated animals (DIVA tests). Here, antigenic preparations (hot-saline extracts and formalin-inactivated bacterins) from two Salmonella Enteritidis rough mutants, carrying either intact (SEΔwaaL) or deep-defective (SEΔgal) LPS-Core, were used in combination with EDA. Biotinylated bacterins, in particular SEΔwaaL bacterin, decorated with EDAvidin (EDA and streptavidin fusion protein) improved the protection conferred by hot-saline or bacterins alone and prevented significantly the virulent infection at least to the levels of live attenuated rough mutants. These findings demonstrate the adjuvant effect of EDAvidin when administered with biotinylated bacterins from Salmonella Enteritidis lacking O-PS and the usefulness of BEDA-SEΔwaaL as non-live vaccine in the mouse model.
- Antigenic Preparation
- Negative Control Seron
- Rough Mutant
- Chloramphenicol Resistance Cassette
- Serological Diagnostic Test
Fibronectin is a dimer, with monomers comprising three types (I, II and III) of homologous repeat units . Three of its alternatively spliced exons (IIIA, IIIB and IIIC, also referred to as EDA -Extra domain A-, EDB -Extra domain B- and III-CS) correspond to the type III repeat unit . EDA and EDB are produced in vivo in response to tissue injury or other warning signals. Particularly, EDA is produced during embryonic development and in rheumatoid arthritis, wound healing, epithelial fibrosis, vascular intimae proliferation or inflammation in adults [3, 4]. EDA induces NF-κB factor activation, proteoglycan release, and 1, 2 and 9 metalloproteinase production, involved in connective tissue destruction following lesion development, as well as in monocyte and dendritic cell migration through the basal membrane. Such events are triggered in response to the interaction between EDA and its specific Toll Like Receptor 4 (TLR-4), which also binds to lipopolysaccharide (LPS) of Gram negative bacteria [5, 6]. Hence, EDA has been proposed to induce maturation of dendritic cells through TLR-4 activation, favouring antigen uptake, expression of co-stimulatory signals, antigen presentation and induction of anti-viral or anti-tumoral T cell responses [6–8]. Recombinant EDA has been expressed in E. coli and tobacco chloroplasts, maintaining its proinflammatory properties . Easy scale-up, high safety standards and an enormous capacity to synthesize and accumulate foreign proteins in plant chloroplasts  may be advantages of using plants as production platforms for biopharmaceuticals .
Several Salmonella live attenuated strains, including auxotrophic, metabolic and structural (semi-rough) attenuated mutants [11–15] have been proposed as effective vaccines for animals. However, these vaccines are often not safe enough in animals, may release genetically modified microorganisms to the environment and human food-chain, and may interfere in serological diagnostic tests based on the detection of antibodies against the LPS O-Polysaccharide (O-PS)  and/or flagellin , limiting their practical use in sanitary control campaigns. Therefore, most of the currently recommended vaccines against animal salmonellosis include bacterins from smooth attenuated Salmonella spp. . Also, bacterial hot-saline (HS) extracts have been proposed as safe vaccines [19, 20]. Since LPS is a major virulence factor and the LPS O-PS is the immunodominant antigen in serological diagnostic tests, Salmonella mutants lacking LPS O-PS (rough mutants) represent an interesting approach for developing new live attenuated vaccines . In line with this, some rough mutants such as Salmonella Typhimurium ΔrfaH have been proposed as live vaccine candidates [21, 22] but others have been considered either too virulent (such as Salmonella Typhimurium ΔwaaL) to be safe or too attenuated (Salmonella Typhimurium ΔgalE or ΔwaaG mutants) to confer protection against virulent infections, being discarded as vaccine candidates .
This work aims to investigate the adjuvant value of EDA, using HS or bacterins obtained from Salmonella Enteritidis rough mutants differing in LPS-Core composition (SEΔwaaL and SEΔgal) as antigenic preparations, in a sublethal challenge mouse model.
Bacterial wild-type and mutant strains
Oligonucleotides designed and used in this study
Sequence (5′to 3′)
TCACCAGAACAGAACCTGGCGAAT TTAGATGCCACAAGC GTATTTGGAAAGATTCATTA AGTGTAGGCTGGAGCTGCTTCa
AGTTGGGAAAATGTAGCGCAGCG TTTCGAGGAACAAAT GAAAAACTGGTTTGATAAGTG ACATATGAATATCCTCCTTAGA
Characterization of rough mutants
The absence of LPS O-PS and the differences in size (i.e. in core structure) of the LPS-Core in SEΔwaaL and SEΔgal rough mutants were verified by SDS-PAGE silver staining, modified for LPS identification as described previously . Surface topology was analyzed by susceptibility to 17 Salmonella Enteritidis Typing Phages (SETPs; named from SETP 1 to 17) and Felix O1 (FO; which specifically recognizes the outer LPS-Core of most Salmonella spp.), according to standard protocols [28, 29] of the Salmonella National Reference Laboratory (Instituto de Salud Carlos III, Madrid, Spain). The presence of flagellum antigens was determined by direct anti-H slide agglutination tests  and motility was analyzed by the halo generated in swimming and swarming assays . The outer membrane permeability of the mutants was assessed by both the Minimal Bactericidal Concentration to Polymyxin B using a standard microdilution test [31, 32] and the bactericidal effect of non-immune human serum . Other phenotypic characteristics were assessed as described elsewhere . Finally, virulence studies were performed in BALB/c mice, by determining lethality and splenic infections in surviving mice. For this, mice (n = 5) were inoculated intraperitoneally with 2 × 103, 2 × 105 or 2 × 107 CFU/animal of SEΔwaa L or SEΔgal mutants. A group of mice (n = 5) inoculated with 2 × 103 CFU/mouse of smooth parental SE-wt strain was used as reference. Deaths were recorded for 2 weeks after infection. Then, the percentage of cumulative survival in mice was calculated by the Kaplan-Meier analysis, and statistically compared by the LogRank test (see below). Moreover, the number of viable bacteria was determined in spleens of surviving mice and expressed as the mean ± SD of log10 CFU/spleen, as described previously .
Production and characterization of antigenic preparations
Recombinant protein EDA was obtained either in E. coli BL21(DE3) cells (Amersham Pharmacia Biotech) or tobacco plant chloroplasts (named MEDA) as described previously [6, 8]. After filter-sterilization in a 0.2-μm membrane (Millipore), the absence of bacterial contaminants in both EDA preparations was assessed by plating onto agar.
Bacterial antigens were obtained by HS extraction or formalin-inactivation (bacterins) from SEΔgal (HS-SEΔgal and B-SEΔgal), SEΔwaaL (HS-SEΔwaaL and B-SEΔwaaL) and SE-wt (HS-SEwt and B-SEwt) strains, as described previously [19, 34].
To improve binding of EDA to the bacterial cell surface, a recombinant fusion protein of EDA and streptavidin (named EDAvidin) was obtained and mixed with bacterins previously biotinylated to obtain the antigenic preparations named BEDA. EDAvidin was produced from the expression plasmid pET21a-EDA-Streptavidin constructed with the pET21a-Streptavidin-Alive  expressing wild-type subunit of streptavidin with a 6His-tag. The DNA sequence encoding EDA was amplified by PCR, using primers CATATGAACATTGATCGCCCTAAAGGACT (Upper EDA-NdeI) and CATATGTGTGGACTGGATTCCAATCAGGGG (Lower EDA-NdeI) and the plasmid pET20b1-2 as a probe. The resulting PCR product was cloned in pCR2.1-TOPO using the TOPO TA Cloning® kit (Invitrogen LifeTechnologies). All constructs were verified by DNA sequencing. The resulting plasmid expressing EDA in the C-terminus of streptavidin was employed for transformation and expression of EDAvidin in E. coli BL21(DE3) cells, and the fusion protein was purified by affinity chromatography (HisTrapTM HP columns, GE Healthcare Life Sciences). The Sulfo-NHS-SS-Biotin system (ThermoScientific) was used for bacterin biotinylation, and the non-reacting Sulfo-NHS-SS-Biotin molecules were removed by dialysis using a Slide-a-Lyzer Dialysis cassette (3,500-MWCO, ThermoScientific). To determine the level of free amines, bacterins B-SEΔgal, B-SEΔwaaL and B-SEwt were labeled with carboxyfluorescein succinimidyl ester (CFSE) 0.125 μM (Invitrogen), washed twice and analysed by flow cytometry. Unlabeled SE-wt bacterins were used as negative control.
LPS was quantified by detecting 2-keto-3-deoxyoctonate (Kdo) corrected for 2-deoxyaldoses, as described previously . Protein and antigenic profiles of bacterial and recombinant protein preparations were analysed by Coomassie (Bio-Rad) and immunoblotting methods, respectively. Where indicated, samples were also loaded without boiling onto the SDS-polyacrylamide gels in order to visualize the presence of tetramers of the EDAvidin fusion protein. Immunoblotting was performed using sera from mice experimentally infected with smooth SE-wt or from EDA hyperimmunized rabbits as primary antibodies and horseradish anti-mouse IgG or goat anti-rabbit IgG (ThermoFisher) as secondary antibodies, and the reaction was developed with diaminobenzidine. Proteins were quantified by the Bradford method (Bio-Rad).
Finally, the ability of EDAvidin to bind biotinylated and non-biotinylated bacterins was assessed by ELISA in plates coated with 0.1 μg/well of biotinylated bacterins or conventional bacterins as control. After incubation with 10% foetal calf serum (Invitrogen LifeTechnologies), 3 μg/mL of EDA or EDAvidin proteins were added, incubated with anti-EDA rabbit polyclonal antibody and anti-rabbit whole IgG horseradish peroxidase conjugated antibody (Sigma). The final reactions were developed with tetra-methyl-benzidine substrate (BD Biosciences), stopped with 2 N H2SO4, and read at 450 nm in a Multiskan Ascent apparatus (ThermoElectron).
Efficacy of immunization and antibody responses assessment
Eight to ten-week old female BALB/c mice (Charles River International) were accommodated (Public University of Navarre registration code ES/31-2016-000002-CR-SU-US) and handled in compliance with the current European, national and local (RD 1201/2005) regulations, following the FELASA and ARRIVE guidelines and with the approval of the UPNA Animal Experimentation Committee and Navarre’s Government. For immunization, mice were inoculated intraperitoneally (IP) with a volume of 0.1 mL of live bacteria or antigenic preparations in PBS. Bacterial suspensions were adjusted by spectrophotometry in PBS (O.D. at 600 nm = 0.150 contains approximately 2 × 108 CFU/mL) and the exact number of CFU in each suspension was retrospectively assessed, by serial dilutions and plating on agar. Efficacy was determined from at least two independent experiments with statistically equivalent controls.
In a first set of experiments, a total of 30 mice (6 groups; 5 mice/group) were IP immunized with HS or bacterin preparations (20 μg protein/mouse), alone or in physical mix with EDA or MEDA (40 μg/mouse). A total of 45 control mice (9 groups; 5 mice/group) were inoculated with: (i) HS-SEwt or B-SEwt (20 μg protein); (ii) PBS; or (iii) EDA or MEDA (40, 100 or 200 μg/mouse). Four weeks later, all mice were challenged IP with the optimal sub-lethal dose of around 2.5 × 102 CFU SE-wt and, 4 days later, the mean (n = 5) number of log10 CFU/spleen challenging strain was determined . The optimal sub-lethal dose (i.e., the minimal dose able to induce moderate and homogeneous levels of splenic infection in all mice) was estimated in a previous dose–response experiment, where mice (n = 5) were IP inoculated with 50, 100, 250, 500 or 1000 CFU/mouse, and log10 CFU/spleen determined 4 days later.
A similar immunization-challenge murine model (but using 4 mice/group) was applied in a second set of experiments, to determine the efficacy of biotinylated bacterins (20 μg/mouse) bound to EDAvidin (75 μg/mouse) (i.e. BEDA-SEΔwaaL and BEDA-SEΔgal, respectively). Besides the above-mentioned controls, live SEΔwaaL or SEΔgal live mutants (1 × 104 CFU/animal, IP) were included. Persistence of SEΔwaaL at the end of the experimental period was distinguished from that of SE-wt challenging strain by double plating in agar and agar supplemented with chloramphenicol (20 mg/L). Persistence of SEΔgal was not determined since this mutant was cleared from spleens within 2 weeks post-inoculation, as verified in the virulence assay (Additional file 1: Table S1).
Just before challenge, mice sera were analysed for Salmonella specific immunoglobulin (IgG + IgM and IgG2a/IgG1) quantification by indirect ELISA, using HS extracts (HS-SEwt for IgG + IgM or homologous HS extract for IgG2a/IgG1 isotype determination) as coating antigens and horseradish anti-mouse IgG and IgM (H + L) (InmunoPure, Pierce) or anti-mouse IgG1 or IgG2a (Nordic Immunological) as conjugates. Positive control sera from mice experimentally infected with SE-wt, and negative control sera from animals inoculated with PBS were included in each ELISA plate. Serum titre was defined as the reciprocal of the highest serum dilution showing a mean O.D. value equal to or higher than that of the negative control sera (n = 4) obtained from mice inoculated with PBS, plus 3 times the SD. Titers of IgG + IgM were expressed as the mean and SD of individual log10 titre obtained; and the Th1/Th2 balance, as the mean and SD of individual log10 IgG2a/log10 IgG1 ratio .
Kolmogorov-Smirnov test was first applied to assess the normal distribution of data. Then, means were statistically compared by a one-way ANOVA test, followed by the Fisher’s Protected Least Significant Difference (PLSD) test (when four or less groups were compared) or Bonferroni’s test (when more than four groups were compared). Efficacy was determined, from at least two independent experiments with statistically equivalent controls, by statistical comparison of the mean (n = 5) log10 SE-wt CFU/spleen obtained in immunized vs. control mice. In mice survival assays, the percentage of cumulative survival was calculated by the Kaplan-Meier analysis, and statistically compared by the LogRank (Mantel-Cox) test.
Characterization of SEΔwaaL and SEΔgal LPS O-PS deficient mutants
Finally, virulence was measured by the ability of bacteria to induce lethality in the infected mice (Additional file 1: Table S1). As expected, all mice inoculated with 2 × 103 CFU of the strain SE-wt died (at day four) after inoculation. However, none (SEΔgal) or only one (SEΔwaa L) of the mice inoculated with this dose succumbed at the end of the experiment (2 weeks post-inoculation), indicating that both rough mutants were less (p = 0.0027 in LogRank test) virulent than the smooth parental strain SE-wt. Virulence differences were also observed between both rough mutants, since all mice infected with SEΔgal, at any dose, survived to the end of the experimental period without signs of pain or illness, while those inoculated with SEΔwaa L showed increased (p = 0.035) lethality in cumulative survival analysis when infected at the highest dose, either at day 5 (all the mice inoculated with 2 × 107 CFU/mouse died) or at day 12 (50% of cumulative survival in animals inoculated with 2 × 105 CFU/mouse) (Additional file 1: Table S1). Similarly, highly significant (p < 0.005) differences between both rough mutants were observed in the levels of splenic infections found in surviving mice (Additional file 1: Table S1), irrespectively of the infection dose used. Mice inoculated with 2 × 103 or 2 × 105 CFU of SEΔgal were practically (1.3 and 1.6 mean log CFU/spleen, respectively) cleared from infection at week 2, and those infected at a high dose (2 × 107 CFU) were only moderately infected (3.6 mean log CFU). Finally, all surviving mice infected with 2 × 103 or 2 × 105 CFU of SEΔwaa L retained more than 4.4 mean log CFU in spleen.
Characterization of antigen preparations and enhancement of EDA binding to antigen
According to SDS-PAGE and Western-Blot with anti-His or anti-EDA antibodies, purified EDA and MEDA recombinant proteins had the expected molecular weights (13 and 16 KDa, respectively) [8, 39]. Regarding EDAvidin, a 24 KDa band was observed in SDS-PAGE gels (Figure 2b). However, native (unboiled) EDAvidin formed one band likely corresponding to a multimeric form (between 100 and 150 KDa).
Since the biotinylation process involves the binding of Sulfo-NHS-LC biotin to free amines on the bacterial wall, the decreased binding of bacterin SEΔwaaL mutant to EDAvidin with respect to SEΔgal or SE-wt could be related to a decreased level of biotinylation of this mutant. The flow cytometry results after CFSE labelling (Additional file 3: Figure S2) revealed that bacterin SEΔwaaL had a significantly weaker labeling compared to SEΔgal or SE-wt, in agreement with the results of Figure 3 and the hypothesis proposed.
EDA/MEDA increases the efficacy of bacterins obtained from LPS O-PS deficient antigens
In the dose–response assay with the virulent strain SE-wt, mice inoculated with 50 or 100 CFU showed inconsistent infections and those inoculated with 500 or 1000 CFU showed saturating infections (Additional file 4: Table S2) with signs of septic shock close to death. In consequence, 2.5 × 102 CFU/mouse was chosen as the optimal sub-lethal dose of challenge in the efficacy experiments.
The effect of EDA on protection was studied in mice (n = 5) immunized with HS or bacterins from isogenic rough mutants administered in a simple physical mix with EDA (HS and bacterins) or MEDA (only bacterins) and challenged 4 weeks later with a sublethal dose of SE-wt. In the absence of EDA/ MEDA, vaccination with HS-SEwt or B-SEwt (positive controls of protection) prevented virulent infection, whereas mice unvaccinated (PBS control group) reached around 7 log CFU/spleen (Figure 4). Immunization with HS-SEΔwaaL, HS-SEΔgal or B-SEΔgal did not prevent the virulent infection, reaching a mean log CFU of SE-wt in spleen statistically equivalent to that of the PBS control group (Figure 4). In contrast, B-SEΔwaaL alone conferred significant protection (P = 0.001 vs. PBS control), superior to that conferred by B-SEΔgal (P < 0.0001 between both mutants). The combined administration of EDA in preparations with rough HS extracts did not improve protection significantly compared to administration of these antigens alone. Finally, when using bacterins, EDA and MEDA improved significantly (P < 0.001) the protection conferred by B-SEΔgal (Figure 4b) but not or only moderately that conferred by B-SEΔwaa L (Figure 4a).
Increased binding of EDA to the antigen enhances protection and antibody production
In order to determine whether a strong binding of EDA to the surface of bacterins might improve immunogenicity, biotinylated bacterins mixed with the EDAvidin (giving rise to the BEDA bacterins) were used for immunization, using live rough mutants as reference. All mice were challenged with the SE-wt strain at week 4 after immunization and the number of SE-wt and SEΔwaaL determined in spleen 4 days later. Mice vaccinated with the rough mutants were found less (P < 0.05) protected than those immunized with B-SEwt (positive controls). Mice immunized with SEΔwaaL mutant retained 3.85 ± 0.21 log10 CFU of the mutant in their spleens, revealing the persistence of this mutant throughout the experimental period, with infection levels similar to those observed by this mutant at week 2 (Additional file 1: Table S1). As shown in Figure 4, both BEDA-SEΔwaaL and BEDA-SEΔgal preparations improved significantly the levels of protection compared to the bacterin administered either alone (P < 0.001) or mixed just with EDA (P ≤ 0.03). Strikingly, the efficacy of BEDA-SEΔwaaL and BEDA-SEΔgal was, respectively, similar to (P > 0.05) and higher than (P ≤ 0.01) that conferred by the isogenic live rough mutants. Finally, live rough mutants were less (P < 0.05) effective than B-SEwt, whereas BEDA-SEΔwaaL conferred a protection statistically equivalent to this positive control (B-SEwt), 2 out 4 mice being free from virulent infection. Therefore, the increased binding of EDA to antigens favoured by streptavidin-biotin interactions resulted in enhanced protection.
Immunoglobulin titres (IgG plus IgM mean log titers and IgG2a/IgG1 log ratios) in mice, measured at week 4 after immunization with bacterins, either physically mixed just with EDA or bound to EDA (EDAvidin) by streptavidin-biotin (BEDA) interaction
Log10 IgM + IgG
Log10 IgG2a/IgG1 ratio
(mean ± SD) a
(mean ± SD) a
3.45 ± 0.17
1.18 ± 0.26
3.60 ± 0.73
1.21 ± 0.10
2.02 ± 0.45
1.05 ± 0.07
B-SEΔwaaL + EDA
2.54 ± 0.38
1.05 ± 0.20
B-SEΔgal + EDA
2.69 ± 0.42
0.85 ± 0.12
2.77 ± 0.51
1.45 ± 0.20
3.07 ± 0.51
0.74 ± 0.09
Many live attenuated or inactivated vaccines against a variety of pathogens such as Salmonella require booster immunizations to attain the expected protection. Since vaccine efficacy may increase with the use of adjuvants, research on adjuvant performance is necessary. In this context, the positive effect of EDA, when administered with non-live Salmonella antigenic preparations, was studied in a vaccination-challenge mouse model involving two Salmonella Enteritidis rough mutants (SEΔwaaL and SEΔgal) differing in the LPS-Core composition. None of these mutants produced LPS O-PS antigen, which may help to distinguish animals vaccinated with these mutants from those infected by field strains. The absence of either (O-PS)-to-LPS assembly enzymes (SEΔwaaL) or LPS-Core galactose synthesis enzymes (SEΔgal) led to an intact (in SEΔwaaL) or a defective (in SEΔgal) LPS-Core, according to results on SDS-PAGE and susceptibility to SEPTs bacteriophages, as expected from the genetic design of these mutants and previous findings on similar mutants [20, 22, 40, 41]. Functional mutants in the gal operon, which includes gal E, gal T, gal K and gal M genes, all involved in the synthesis of the LPS-Core galactose , have been obtained by inactivation of the galE gene , but these single-gene mutants may revert to a smooth-LPS by incorporating exogenous precursors of galactose into the biosynthetic pathway, both in vitro and in vivo[21, 43, 44]. Thus, the mutant production strategy applied in this work, based on the use of a complete deletion of gal operon to produce the SEΔgal mutant, ensured the rough phenotype of this mutant through the blockage of galactose synthesis from endogenous or exogenous sources .
When attempting the design of non-live vaccines, HS extracts (enriched in outer membrane components) and formalin-inactivated bacteria (bacterins that retain all the external and internal bacterial antigens) were used as antigens [19, 37]. Differences in vaccine efficacy between studies using Salmonella Enteritidis HS extracts in mice [19, 45] could be explained by differences in bacterial genetic makeup, extract preparation and enrichment methods or immunization vehicles. The HS preparations obtained from the Salmonella Enteritidis rough mutants reported here did not protect mice against a virulent challenge, whereas mice immunized with HS-SEwt were protected (100% mouse survival and 80% uninfected spleens), demonstrating the essential role of the LPS O-PS in HS-driven protection. The physicochemical characterization of antigenic preparations confirmed that bacterins had a broader protein spectrum compared to HS extracts. This difference could be related to differences in preparation methods (boiling, ultracentrifugation and dialysis for HS extracts and not bacterins). Bacterins lacking LPS O-PS may be useful vaccines against heterologous Salmonella species and serovars, since the rough phenotype has an enhanced immunogenicity of minor antigens, mainly porins and lipoproteins conserved in Salmonella serotypes . Interestingly, B-SEΔwaaL induced partial protection in mice whereas B-SEΔgal did not confer protection, indicating that a complete LPS-Core could play an essential role.
Once verified that the protection obtained with HS or bacterins from both rough mutants was below that of the B-SEwt, the potential of EDA as immunopotentiator in non-live bacterial vaccines was assessed. Adjuvants such as Freund’s complete or aluminium hydroxide do not appear to improve the immune response against Salmonella[46, 47], in contrast with polymeric carriers used to adsorb or encapsulate bacterial extracts [19, 48]. Alternatively, adjuvants interacting directly with TLRs have successfully immunopotentiated Salmonella Enteritidis sub-cellular fractions. Examples are polyinosinic:polycytidylic acid [poly(I:C)] with TLR-3 , CpG sequences with TLR-9  and bacterial LPS with TLR-4 [46, 50]. Since EDA activates TLR4 favouring viral antigen presentation [6–8, 39], mice were immunized in the presence of recombinant EDA (produced in E. coli) or MEDA (in transformed plant chloroplast), initially as a simple physical mix with HS extracts (EDA) or bacterins (EDA and MEDA) from Salmonella rough mutants.
The effect of EDA in the efficacy of immunizations depended on the type of antigenic preparation (found in bacterins and not HS extracts) and the mutant from which the bacterins were prepared (B-SEΔwaaL or B-SEΔgal). No significant adjuvant effects were observed with EDA or MEDA treatments when B-SEΔwaaL was administered alone (which already conferred partial protection), but both EDA or MEDA significantly enhanced protection when using B-SEΔgal. This suggests that the size and/or composition of LPS-Core may have affected the affinity for TLR-4 and/or may have regulated the intracellular fate of the antigen in dendritic cells, as demonstrated for LPS O-PS antigen . Possibly, the complete (but not the incomplete) LPS-Core antigen competes with EDA for TLR-4 recognition, so that EDA is not free to interact with this receptor. Alternatively, EDA and MEDA may have a higher affinity for their surface receptors when exposed in absence of the external LPS-Core (i.e. B-SEΔgal).
In search of strategies that would help to enhance the binding of EDA to the antigen, the novel recombinant EDA fused to streptavidin molecule (EDAvidin) allowed a significant binding to biotinylated bacterins. Most likely, biotinylated bacterins decorated with EDAvidin enhanced the targeting of LPS defective bacterins to TLR4 expressing cells, modulating the entry of the antigen and/or its intracellular fate and/or the persistence in dendritic cells  to favour the enhancement of the efficacy of these antigenic preparations. This is in line with the significantly improved protection conferred by BEDA-SEΔwaaL and BEDA-SEΔgal complexes compared to bacterins alone, reaching levels similar to those obtained with the live rough mutants and, in the case of BEDA-SEΔwaaL, the levels conferred by the bacterin B-SEwt positive control. Irrespective of the decreased binding of SEΔwaaL to EDAvidin (apparently related to a lower level of biotinylation according to flow cytometry results using CFSE), the protection conferred by each individual bacterin including SEΔwaaL increased significantly in the presence vs. absence of EDAvidin. Altogether, these findings demonstrate that EDA in the form of EDAvidin-biotin complexes improves the efficacy of non-live vaccines. Like in previous work , increased IgG + IgM levels or a Th1 biased response (according to the IgG2a/IgG1 balance) could not be correlated with the protection conferred by both BEDA preparations (BEDA-SEΔwaaL and BEDA-SEΔgal), even though the immune response must have been in both cases sufficiently enhanced to confer significant protection.
Most studies in mice designed to assess Salmonella vaccine efficacy use a lethal challenge model. Here, we have used a sub-lethal dose challenge model  to preserve animal welfare, yielding information in line with that obtained with the lethal challenge model, since e.g. here live SEΔwaaL performed better than SEΔgal, like in previous lethal challenge reports with similar mutants . At the same time, this model allowed the detection of increased protection in mice when EDA or MEDA were administered mixed with B-SEΔgal, and also allowed both the selection of bacterins and not HS from both mutants as Salmonella antigen candidates and the detection of enhanced protection with EDAvidin bound to biotinylated B-SEΔwaaL.
Although additional work should be done in different natural hosts to determine the true innocuousness and efficacy of BEDA preparations, it is clear that EDA (as EDAvidin) improves the efficacy of rough Salmonella bacterins (as biotinylated bacterins) in the mouse model. The association between EDAvidin and B-SEΔwaaL bacterin may be considered safe and effective for use as a non-live vaccine, conferring a high protection against virulent infection. Employing this BEDA immunization strategy with O-PS deficient mutants may also help to distinguish (by conventional anti-O-PS or new anti-EDA serological tests) between vaccinated animals and asymptomatically infected carriers, reservoirs of zoonotic infections. Moreover, the use of non-live vaccines avoids the presence of genetically modified microorganisms in farm animals and their subsequent release to environment or food-chain, having an added value for consumers and veterinary use.
This work was funded by Gobierno de Navarra and European Union (project EuroInnova-Navarra reference IIM10865.RI1-EP12). B.S.R., P.M.M. and X.D.A. post-doctoral contracts were granted by Gobierno de Navarra/JAE-doc CSIC, MICINN (Subprograma Juan de la Cierva) and Universidad Pública de Navarra, respectively. We are grateful to A. Echeíta (Instituto de Salud Carlos III, Spain) and I. Moriyón (Universidad de Navarra, Spain), for their helpful assistance and indications on some aspects of bacterial and antigens characterization.
- Petersen TE, Thogersen HC, Skorstengaard K, Vibe-Pedersen K, Sahl P, Sottrup-Jensen L, Magnusson S: Partial primary structure of bovine plasma fibronectin: three types of internal homology. Proc Natl Acad Sci U S A. 1983, 80: 137-141. 10.1073/pnas.80.1.137.PubMed CentralView ArticlePubMedGoogle Scholar
- Bennett VD, Pallante KM, Adams SL: The splicing pattern of fibronectin mRNA changes during chondrogenesis resulting in an unusual form of the mRNA in cartilage. J Biol Chem. 1991, 266: 5918-5924.PubMedGoogle Scholar
- Barilla ML, Carsons SE: Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum. 2000, 29: 252-265. 10.1016/S0049-0172(00)80012-8.View ArticlePubMedGoogle Scholar
- George J, Wang SS, Sevcsik AM, Sanicola M, Cate RL, Koteliansky VE, Bissell DM: Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am J Pathol. 2000, 156: 115-124. 10.1016/S0002-9440(10)64711-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF: The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem. 2001, 276: 10229-10233. 10.1074/jbc.M100099200.View ArticlePubMedGoogle Scholar
- Lasarte JJ, Casares N, Gorraiz M, Hervas-Stubbs S, Arribillaga L, Mansilla C, Durantez M, Llopiz D, Sarobe P, Borras-Cuesta F, Prieto J, Leclerc C: The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol. 2007, 178: 748-756.View ArticlePubMedGoogle Scholar
- Mansilla C, Gorraiz M, Martinez M, Casares N, Arribillaga L, Rudilla F, Echeverria I, Riezu-Boj JI, Sarobe P, Borras-Cuesta F, Prieto J, Lasarte JJ: Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. J Hepatol. 2009, 51: 520-527. 10.1016/j.jhep.2009.06.005.View ArticlePubMedGoogle Scholar
- Farrán I, McCarthy-Suarez I, Rio-Manterola F, Mansilla C, Lasarte JJ, Mingo-Castel AM: The vaccine adjuvant extra domain A from fibronectin retains its proinflammatory properties when expressed in tobacco chloroplasts. Planta. 2010, 231: 977-990. 10.1007/s00425-010-1102-4.View ArticlePubMedGoogle Scholar
- Oey M, Lohse M, Kreikemeyer B, Bock R: Exhaustion of the chloroplast protein synthesis capacity by massive expression of a highly stable protein antibiotic. Plant J. 2009, 57: 436-445. 10.1111/j.1365-313X.2008.03702.x.View ArticlePubMedGoogle Scholar
- Daniell H, Singh ND, Mason H, Streatfield SJ: Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci. 2009, 14: 669-679. 10.1016/j.tplants.2009.09.009.PubMed CentralView ArticlePubMedGoogle Scholar
- Kwon HJ, Cho SH: Pathogenicity of SG 9R, a rough vaccine strain against fowl typhoid. Vaccine. 2011, 29: 1311-1318. 10.1016/j.vaccine.2010.11.067.View ArticlePubMedGoogle Scholar
- Kong Q, Yang J, Liu Q, Alamuri P, Roland KL, Curtiss R: Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar typhimurium. Infect Immun. 2011, 79: 4227-4239. 10.1128/IAI.05398-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Mastroeni P, Chabalgoity JA, Dunstan SJ, Maskell DJ, Dougan G: Salmonella: immune responses and vaccines. Vet J. 2001, 161: 132-164. 10.1053/tvjl.2000.0502.View ArticlePubMedGoogle Scholar
- Karasova D, Sebkova A, Vrbas V, Havlickova H, Sisak F, Rychlik I: Comparative analysis of Salmonella enterica serovar Enteritidis mutants with a vaccine potential. Vaccine. 2009, 27: 5265-5270. 10.1016/j.vaccine.2009.06.060.View ArticlePubMedGoogle Scholar
- Leyman B, Boyen F, Van Parys A, Verbrugghe E, Haesebrouck F, Pasmans F: Salmonella Typhimurium LPS mutations for use in vaccines allowing differentiation of infected and vaccinated pigs. Vaccine. 2011, 29: 3679-3685. 10.1016/j.vaccine.2011.03.004.View ArticlePubMedGoogle Scholar
- Barrow PA: Use of ELISAs for monitoring Salmonella in poultry. Vet Rec. 1994, 134: 99-View ArticlePubMedGoogle Scholar
- Proux K, Jouy E, Houdayer C, Protais J, Dibb-Fuller M, Boscher E, Gillard A, Gracieux P, Gilbert F, Beaumont C, Duchet-Suchaux M: Reliable ELISAs showing differences between resistant and susceptible lines in hens orally inoculated with Salmonella Enteritidis. Vet Res. 2002, 33: 23-33. 10.1051/vetres:2001003.View ArticlePubMedGoogle Scholar
- OIE: Office International des Épizooties: Manual of Diagnostic Tests & Vaccines for Terrestrial Animals. 2008, 1267-1283. 6Google Scholar
- Estevan M, Irache JM, Grilló MJ, Blasco JM, Gamazo C: Encapsulation of antigenic extracts of Salmonella enterica serovar Abortusovis into polymeric systems and efficacy as vaccines in mice. Vet Microbiol. 2006, 118: 124-132. 10.1016/j.vetmic.2006.07.004.View ArticlePubMedGoogle Scholar
- Nagy G, Palkovics T, Otto A, Kusch H, Kocsis B, Dobrindt U, Engelmann S, Hecker M, Emody L, Pal T, Hacker J: “Gently rough”: the vaccine potential of a Salmonella enterica regulatory lipopolysaccharide mutant. J Infect Dis. 2008, 198: 1699-1706. 10.1086/593069.View ArticlePubMedGoogle Scholar
- Germanier R: Immunity in Experimental Salmonellosis I. Protection Induced by Rough Mutants of Salmonella Typhimurium. Infect Immun. 1970, 2: 309-315.PubMed CentralPubMedGoogle Scholar
- Nagy G, Danino V, Dobrindt U, Pallen M, Chaudhuri R, Emody L, Hinton JC, Hacker J: Down-regulation of key virulence factors makes the Salmonella enterica serovar Typhimurium rfaH mutant a promising live-attenuated vaccine candidate. Infect Immun. 2006, 74: 5914-5925. 10.1128/IAI.00619-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Solano C, Garcia B, Valle J, Berasain C, Ghigo JM, Gamazo C, Lasa I: Genetic analysis of Salmonella Enteritidis biofilm formation: critical role of cellulose. Mol Microbiol. 2002, 43: 793-808. 10.1046/j.1365-2958.2002.02802.x.View ArticlePubMedGoogle Scholar
- Datsenko KA, Wanner BL: One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 2000, 97: 6640-6645. 10.1073/pnas.120163297.PubMed CentralView ArticlePubMedGoogle Scholar
- García B, Latasa C, Solano C, García-del Portillo F, Gamazo C, Lasa I: Role of the GGDEF protein family in Salmonella cellulose biosynthesis and biofilm formation. Mol Microbiol. 2004, 54: 264-277. 10.1111/j.1365-2958.2004.04269.x.View ArticlePubMedGoogle Scholar
- Solano C, Garcia B, Latasa C, Toledo-Arana A, Zorraquino V, Valle J, Casals J, Pedroso E, Lasa I: Genetic reductionist approach for dissecting individual roles of GGDEF proteins within the c-di-GMP signaling network in Salmonella. Proc Natl Acad Sci U S A. 2009, 106: 7997-8002. 10.1073/pnas.0812573106.PubMed CentralView ArticlePubMedGoogle Scholar
- Tsai CM, Frasch CE: A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem. 1982, 119: 115-119. 10.1016/0003-2697(82)90673-X.View ArticlePubMedGoogle Scholar
- Ward LR, de Sa JD, Rowe B: A phage-typing scheme for Salmonella Enteritidis. Epidemiol Infect. 1987, 99: 291-294. 10.1017/S0950268800067765.PubMed CentralView ArticlePubMedGoogle Scholar
- De Lappe N, Doran G, O’Connor J, O’Hare C, Cormican M: Characterization of bacteriophages used in the Salmonella enterica serovar Enteritidis phage-typing scheme. J Med Microbiol. 2009, 58: 86-93. 10.1099/jmm.0.000034-0.View ArticlePubMedGoogle Scholar
- Holzer SU, Schlumberger MC, Jackel D, Hensel M: Effect of the O-antigen length of lipopolysaccharide on the functions of Type III secretion systems in Salmonella enterica. Infect Immun. 2009, 77: 5458-5470. 10.1128/IAI.00871-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Sanchez-Gomez S, Lamata M, Leiva J, Blondelle SE, Jerala R, Andra J, Brandenburg K, Lohner K, Moriyon I, Martinez-de-Tejada G: Comparative analysis of selected methods for the assessment of antimicrobial and membrane-permeabilizing activity: a case study for lactoferricin derived peptides. BMC Microbiol. 2008, 8: 196-10.1186/1471-2180-8-196.PubMed CentralView ArticlePubMedGoogle Scholar
- Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Yolken RH: Manual of Clinical Microbiology. 2003, ASM Press, Washington, D.C, 8Google Scholar
- Caro-Hernández P, Fernández-Lago L, De Miguel MJ, Martín-Martín AI, Cloeckaert A, Grilló MJ, Vizcaíno N: Role of the Omp25/Omp31 family in outer membrane properties and virulence of Brucella ovis. Infect Immun. 2007, 75: 4050-4061. 10.1128/IAI.00486-07.PubMed CentralView ArticlePubMedGoogle Scholar
- Blasco JM, Gamazo C, Winter AJ, de Bagüés MP Jiménez, Marín C, Barberán M, Moriyón I, Alonso-Urmeneta B, Díaz R: Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. Vet Immunol Immunopathol. 1993, 37: 257-270. 10.1016/0165-2427(93)90198-D.View ArticlePubMedGoogle Scholar
- Howarth M, Chinnapen DJ, Gerrow K, Dorrestein PC, Grandy MR, Kelleher NL, El-Husseini A, Ting AY: A monovalent streptavidin with a single femtomolar biotin binding site. Nat Methods. 2006, 3: 267-273. 10.1038/nmeth861.PubMed CentralView ArticlePubMedGoogle Scholar
- Osborn MJ, Rosen SM, Rothfield L, Horecker BL: Biosynthesis of bacterial lipopolysaccharide. I. Enzymatic incorporation of galactose in a mutant strain of Salmonella. Proc Natl Acad Sci U S A. 1962, 48: 1831-1838. 10.1073/pnas.48.10.1831.PubMed CentralView ArticlePubMedGoogle Scholar
- Grilló MJ, Manterola L, De Miguel MJ, Muñoz PM, Blasco JM, Moriyón I, López-Goñi I: Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants. Vaccine. 2006, 24: 2910-2916. 10.1016/j.vaccine.2005.12.038.View ArticlePubMedGoogle Scholar
- House JK, Smith BP, O’Connell K, VanMetre DC: Isotype-specific antibody responses of cattle to Salmonella Dublin lipopolysaccharide and porin following Salmonella Dublin vaccination and acute and chronic infection. J Vet Diagn Invest. 2001, 13: 213-218. 10.1177/104063870101300305.View ArticlePubMedGoogle Scholar
- San Román B, De Andrés X, Muñoz PM, Obregón P, Asensio AC, Garrido V, Mansilla C, Arribillaga L, Lasarte JJ, De Andrés D, Amorena B, Grilló MJ: The extradomain A of fibronectin (EDA) combined with poly(I:C) enhances the immune response to HIV-1 p24 protein and the protection against recombinant Listeria monocytogenes-Gag infection in the mouse model. Vaccine. 2012, 30: 2564-2569. 10.1016/j.vaccine.2012.01.081.View ArticlePubMedGoogle Scholar
- Bjur E, Eriksson-Ygberg S, Rhen M: The O-antigen affects replication of Salmonella enterica serovar Typhimurium in murine macrophage-like J774-A.1 cells through modulation of host cell nitric oxide production. Microbes Infect. 2006, 8: 1826-1838. 10.1016/j.micinf.2006.02.025.View ArticlePubMedGoogle Scholar
- Hone D, Morona R, Attridge S, Hackett J: Construction of defined galE mutants of Salmonella for use as vaccines. J Infect Dis. 1987, 156: 167-174. 10.1093/infdis/156.1.167.View ArticlePubMedGoogle Scholar
- Grossiord B, Vaughan EE, Luesink E, de Vos WM: Genetics of galactose utilisation via the Leloir pathway in lactic acid bacteria. Lait. 1998, 78: 77-84. 10.1051/lait:1998110.View ArticleGoogle Scholar
- Clarke RC, Gyles CL: Galactose epimeraseless mutants of Salmonella Typhimurium as live vaccines for calves. Can J Vet Res. 1986, 50: 165-173.PubMed CentralPubMedGoogle Scholar
- Germanier R, Furer E: Immunity in experimental salmonellosis II. Basis for the avirulence and protective capacity of gal E mutants of Salmonella Typhimurium. Infect Immun. 1971, 4: 663-673.PubMed CentralPubMedGoogle Scholar
- Huang CF, Wang CC, Wu TC, Wu KG, Lee CC, Peng HJ: Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice. J Pediatr Gastroenterol Nutr. 2008, 46: 262-271. 10.1097/MPG.0b013e318156050d.View ArticlePubMedGoogle Scholar
- Udhayakumar V, Muthukkaruppan V: Protective immunity induced by porin against Salmonella infection in mice. Indian J Med Res. 1989, 89: 121-127.PubMedGoogle Scholar
- Masoud H: LPS-based conjugate vaccines composed of saccharide antigens of smooth-type Salmonella Enteritidis and rough-type Salmonella Gallinarum 9R bound to bovine serum albumin. Scand J Infect Dis. 2007, 39: 315-322. 10.1080/00365540601034782.View ArticlePubMedGoogle Scholar
- Ochoa J, Irache JM, Tamayo I, Walz A, DelVecchio VG, Gamazo C: Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice. Vaccine. 2007, 25: 4410-4419. 10.1016/j.vaccine.2007.03.025.View ArticlePubMedGoogle Scholar
- George A, Shroff KE, Rath S, Ghosh SN, Sengupta SR, Kamat RS: Route-related variation in the immunogenicity of killed Salmonella Enteritidis vaccine: role of antigen presenting cells. Microbiol Immunol. 1989, 33: 479-488.View ArticlePubMedGoogle Scholar
- Muthukkumar S, Muthukkaruppan VR: Mechanism of protective immunity induced by porin-lipopolysaccharide against murine salmonellosis. Infect Immun. 1993, 61: 3017-3025.PubMed CentralPubMedGoogle Scholar
- Zenk SF, Jantsch J, Hensel M: Role of Salmonella enterica lipopolysaccharide in activation of dendritic cell functions and bacterial containment. J Immunol. 2009, 183: 2697-2707. 10.4049/jimmunol.0900937.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.